Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Aims to further advance efforts to identify novel small molecule LRRK2 inhibitors
December 8, 2015
By: Kristin Brooks
Managing Editor, Contract Pharma
Charles River Laboratories has expanded its collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) for the development of small molecule LRRK2 inhibitors. The work will build on previous research that advanced efforts to identify novel small molecule LRRK2 inhibitors. The inhibition of the kinase LRRK2, which has been genetically linked to development of PD, is one of the most promising therapeutic strategies. The goal is to determine optimal dosing strategies to achieve efficacy with LRRK2 inhibitors while avoiding the lung alterations that have been reported in previous research. “Since 2011, we have worked together with The Michael J. Fox Foundation and its partners to accelerate the discovery of therapies and potential cures for Parkinson’s disease,” said Dr. Emily Hickey, corporate senior vice president, Global Discovery Services, Charles River. “We are delighted to have the opportunity to continue to contribute to this cutting-edge research.” “Continued research into LRRK2 is extremely important to developing a successful therapy to slow or stop the progression of Parkinson’s disease,” said Marco Baptista, PhD, MJFF senior associate director of research programs. “We’re grateful to Charles River for their important work in researching the optimal use strategies of LRRK2.” The pre-competitive Parkinson’s Disease Research Tools Consortium has also provided Charles River funding for its in vitro biology expertise. The consortium will focus on developing a screening assay in human primary cells to observe and modulate protein aggregation and associated neurotoxicity.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !